montirelin and Narcolepsy

montirelin has been researched along with Narcolepsy* in 1 studies

Other Studies

1 other study(ies) available for montirelin and Narcolepsy

Article	Year
Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2000, Volume: 23, Issue:1 The effects on cataplexy and daytime sleep of acute and chronic oral administration of CG-3703, a potent TRH analog were assessed in canine narcolepsy. CG-3703 was found to be orally active and to reduce cataplexy (0.25 to 16 mg/kg) and sleep (8 and 16 mg/kg) in a dose-dependent manner. Two-week oral administration of CG-3703 (16 mg/kg) significantly reduced cataplexy and daytime sleep. The anticataplectic effects of CG-3703 were not associated with changes in general behavior, heart rate, blood pressure, rectal temperature, blood chemistry and thyroid function. Although drug tolerance for the effects on cataplexy and sleep were observed during the second week of chronic drug administration, therapeutic efficacy on cataplexy was improved with individual dose adjustment (final dose range: 16 to 28 mg/kg, p.o.). These results suggest that TRH analogs could be a promising new form of treatment for human narcolepsy. Topics: Animals; Blood Proteins; Body Weight; Catalepsy; Dogs; Female; Male; Narcolepsy; Sleep Stages; Thyrotropin-Releasing Hormone; Thyroxine; Triiodothyronine; Wakefulness	2000

Article

Year

Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2000, Volume: 23, Issue:1

The effects on cataplexy and daytime sleep of acute and chronic oral administration of CG-3703, a potent TRH analog were assessed in canine narcolepsy. CG-3703 was found to be orally active and to reduce cataplexy (0.25 to 16 mg/kg) and sleep (8 and 16 mg/kg) in a dose-dependent manner. Two-week oral administration of CG-3703 (16 mg/kg) significantly reduced cataplexy and daytime sleep. The anticataplectic effects of CG-3703 were not associated with changes in general behavior, heart rate, blood pressure, rectal temperature, blood chemistry and thyroid function. Although drug tolerance for the effects on cataplexy and sleep were observed during the second week of chronic drug administration, therapeutic efficacy on cataplexy was improved with individual dose adjustment (final dose range: 16 to 28 mg/kg, p.o.). These results suggest that TRH analogs could be a promising new form of treatment for human narcolepsy.

Topics: Animals; Blood Proteins; Body Weight; Catalepsy; Dogs; Female; Male; Narcolepsy; Sleep Stages; Thyrotropin-Releasing Hormone; Thyroxine; Triiodothyronine; Wakefulness

2000